| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.072 | 0.2 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |